State of Peptide Purity 2026: How Reliable Research Peptides Really Are

Buyers hear two opposite claims about research peptides — that most are underdosed fakes, and that everything tests at 99%. Neither is a measurement. This report draws on the thousands of independent third-party lab tests aggregated on Peptigrity to separate what the data supports from what it doesn't, and to be clear about what purity testing can and cannot tell you. You can browse the underlying records in our independent lab-test database. Across the shops and peptides we track, the platform's third-party HPLC, endotoxin, and quantity tests describe one thing — product quality and identity — and say nothing about whether a compound is safe or effective. Those are different questions, answered by clinical evidence most of these compounds do not have. Read what follows as a window onto the market, not a verdict on any single vial, and not a reason to buy anything.

How bad is the peptide quality problem, really?

The peptide quality problem is real but uneven, and it concentrates in what never gets tested. Among the most-tested compounds, independent third-party HPLC purity tends to run high — Peptigrity's purity-standards analysis reports averages near 99.6% for semaglutide, 99.0% for BPC-157, and 96.8% for retatrutide — yet the same peptide can range from 85% to 99.5% pure across different brands, and a purity percentage never tells you how many active milligrams are actually in the vial. The pattern that matters is one of selection: products a vendor is willing to send for independent analysis tend to be the ones that pass, while the real risk sits with the majority of vials that are never independently checked at all.

Two caveats sit on top of those averages, and the rest of this report unpacks them. First, an average purity figure hides a wide spread — the 85%-to-99.5% range for a single compound means the brand you buy matters more than the compound you choose. Second, independent academic sampling of randomly purchased online products finds far worse numbers than a database of voluntarily submitted tests does, a gap examined under methodology below. These are the headline independent averages for the most-scrutinised compounds:

Figures are averages from Peptigrity's independent purity analysis across the most-tested compounds; retatrutide — an investigational triple-agonist and the single most-tested compound on the platform — carries the lowest average of the three, though still within the research-grade band.

What does "peptide purity" actually measure (and what it doesn't)?

Peptide purity, as printed on a Certificate of Analysis, is the percentage of total UV peak area in an HPLC chromatogram attributable to the target peptide; the remainder is related substances — truncated chains, deletion sequences, and process residues. A 98% result means 2% of what the detector saw was something other than the intended molecule. The platform sorts results into four purity tiers, and knowing which tier a number falls in matters more than the decimal itself.

That number says nothing, on its own, about whether the vial holds the right peptide, whether it is sterile, whether it carries bacterial endotoxin or heavy metals, or how many milligrams of active peptide you are getting. Identity is a separate question answered by mass spectrometry, which confirms the molecule's weight matches what the label claims — a vial can be highly pure and still be the wrong compound. One practical tell separates a real result from a fabricated one: genuine HPLC peak-area integration produces decimals like 98.47% or 99.12%, whereas a CoA reporting an exact 99.00% suggests a number typed into a document rather than generated by software, one of the red flags catalogued in our guide to Certificate of Analysis red flags. For the assay itself, see why HPLC purity matters. Each assay answers one question and is blind to the others:

Do vials actually contain the labelled amount?

A label that reads "10 mg" describes gross mass, not active peptide. Net peptide content is the gross mass minus the counterion the peptide is paired with during synthesis — typically trifluoroacetate (TFA) or acetate — minus residual water, which alone runs 5–15% by mass after lyophilisation. Because of this, a vial can test at 99% HPLC purity and still contain only 40–70% peptide by weight, with the balance made up of salt and water. Independent quantity testing finds vials deviating from their labels in both directions — overfilled as well as underfilled — and a purity percentage reveals neither.

Independent analysis has put hard numbers on the underfill side for years. A 2015 study in Drug Testing and Analysis, "Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet," found that vials labelled to contain 10 mg actually held between 4.32 and 8.84 mg of peptide — every sample under-delivered, some by more than half. Underfill means a buyer doses less than they think; overfill means more, and a wider dose than intended. Neither is visible from a purity figure, which is why this report treats net content as a quality dimension in its own right. The arithmetic of where the mass goes is straightforward:

Which kinds of quality problems show up most often?

The quality problems that surface in independent testing fall into a few recurring categories: sub-threshold HPLC purity, identity mismatch, net-content deviation, and Certificate of Analysis documentation gaps. Identity mismatches are rarer than purity shortfalls but the most serious, because they mean the vial may not contain the labelled compound at all. In community-documented testing in early 2025, an analytical laboratory correctly flagged samples in which cagrilintide had been supplied as semaglutide, and tirzepatide as retatrutide — different molecules entirely, sold under the wrong name.

Scrutiny concentrates on the most popular compounds. Retatrutide is the most-tested peptide on the platform, ahead of tirzepatide, BPC-157, GHK-Cu, and semaglutide — and the compounds drawing the heaviest demand also draw the closest inspection. This report does not name or rank individual shops or labs; per-vendor judgement belongs on the individual shops and lab-test pages, where each is assessed on its own verifiable record rather than singled out inside a market-wide summary. Independent industry monitoring reinforces which compounds attract the most problematic listings: a December 2025 LegitScript market analysis named melanotan, BPC-157, TB-500, PT-141, and GLP-1 products as the most frequently observed, and noted that unauthorised sellers increasingly use professional-looking sites claiming "high-purity, lab-tested" product.

How was this measured, and can you trust the numbers?

This report aggregates independent third-party tests — HPLC purity, endotoxin screening, and quantity verification — submitted to and verified on Peptigrity across more than two dozen third-party laboratories. The most important caveat is that these are submitted tests, not a randomised survey of the market. They over-represent compounds and sources that get tested, and under-represent products no one independently checks. That is precisely why the platform's averages for popular compounds look strong while academic sampling of randomly purchased online vials looks far grimmer — the difference is selection, not contradiction. We surface this limitation deliberately, because a quality report that hides its own selection bias is doing the same thing it criticises.

This is also the inaugural edition, and the platform's data systems are still maturing, so this report deliberately presents patterns, ranges, and averages rather than precise corpus-wide failure rates — a precision that future editions will add as the dataset is reconciled. The lab-test data is distinct from the platform's trust scores, which combine independent lab purity and verified community reviews in equal weight (50% / 50% as of June 2026, a published method you can read in how we calculate trust scores). The tests aggregated here were processed by laboratories including Janoshik, Freedom Diagnostics, Vanguard, Chromate, and BioRegen, among others profiled in the testing-labs directory — named here only as the source of testing capacity, never ranked or endorsed. For how to weigh a lab's own credibility, see how to evaluate testing-lab trust signals. Peptigrity sells no peptides and takes no advertising, sponsorship, or affiliate revenue, which is what lets this report stay independent of any commercial reason to flatter or attack anyone.

Why does any of this exist?

Most research-peptide active ingredient is synthesised overseas — predominantly in China — then finished, lyophilised, and vialled elsewhere, which is why "Made in USA" on a research-peptide label often describes the finishing step rather than the synthesis. That supply chain, combined with a research-use-only channel that has no pre-market quality gate, is the structural reason quality varies so much from vial to vial; we cover the sourcing reality in where research peptides are manufactured. The regulated alternative — pharmacy compounding — is where 2026's biggest change is unfolding.

As of June 2026, the regulatory picture is moving and should be re-verified before relying on it. The FDA placed 19 peptides on its Category 2 "do not compound" list in September 2023; in February 2026 the HHS Secretary signalled most would be reconsidered; on April 15, 2026 the FDA removed roughly a dozen peptides from Category 2 (effective in late April) through a Federal Register notice (Docket FDA-2025-N-6895) that opened a public-comment window closing in mid-June 2026; and a Pharmacy Compounding Advisory Committee vote is scheduled for July 23–24, 2026 on seven named peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and semax — with a further group slated for review by early 2027. The distinction that matters: moving off Category 2, or onto Category 1, governs whether licensed compounding pharmacies may prepare a peptide under prescription. It does not make any of these compounds an FDA-approved drug. For the full chronology see our 2026 FDA peptide regulation timeline and the compounding pharmacy versus research peptide explainer.

Is peptide quality getting better or worse?

The clearest signal of change is the volume of independent testing itself, which has grown rapidly through 2026 — from a few hundred published tests early in the year to several thousand now. More independent tests per product is the single clearest sign of a market becoming more accountable, regardless of where the purity averages land, because a tested market is a market that can be held to account. Year-over-year change in the quality metrics themselves — average purity, identity-confirmation rate, net-content deviation — is best read against a stable baseline, and this edition is that baseline; the more informative answer will come from comparing editions in the years ahead.

The pattern worth watching is that the newest, most-hyped compounds attract the heaviest scrutiny and show the most variability — retatrutide is both the most-tested compound and the lowest-average-purity of the three headline peptides. Independent clinicians remain cautious about the category as a whole: on his AMA on peptide science and hype, Dr. Peter Attia notes that most popular gray-market peptides fail when placed under scrutiny, and that the absence of human data — not impurity alone — is the deeper concern. For the broader business and supply trends behind these numbers, see our state of the peptide industry overview.

What should you actually do with this?

If you are going to buy regardless — and this report makes no recommendation that you should — a few checks meaningfully reduce, though never eliminate, the risk of a mislabelled or underdosed product. Insist on a recent independent third-party Certificate of Analysis rather than a vendor's own unverifiable claim; check identity with a mass-spec molecular-weight match, not just a purity percentage; account for net content when you calculate a dose, since purity and milligrams-of-active are different numbers; and prefer compounds and sources that carry multiple independent tests over a single self-reported one. None of this makes an unapproved compound safe or appropriate for you — that is a conversation for a licensed healthcare provider.

The practical next step most buyers take from here is learning the full verification workflow, which we cover in how to verify peptide quality before you buy, and comparing sources on their independent records in the shops directory or spotting the warning signs in how to spot a scam peptide shop.

Frequently Asked Questions

Does a high HPLC purity number mean a peptide is safe?

No. Purity measures what fraction of the material is the target peptide — a question about product composition. Safety and effectiveness are different questions answered by clinical evidence, which most research peptides do not have. A pure product can still be the wrong compound, underdosed, non-sterile, or simply unstudied in humans.

Can a vial be 99% pure and still underdosed?

Yes. Purity is the percentage of what is present that is the target peptide; net content is how many milligrams of active peptide are actually in the vial after the counterion salt and residual water are subtracted. Independent testing finds that a 99%-pure powder can be only 40–70% peptide by weight, so it can deliver well under the labelled dose.

Are these numbers a random sample of the whole market?

No. They are independent tests that were submitted and verified, not a randomised survey. Treat them as a directional window onto the market rather than a precise census — the products that get tested are not a random draw from everything on sale. We state this openly because it changes how the figures should be read.

Did the 2026 FDA changes make peptides FDA-approved?

No. Removal from Category 2, or a Category 1 vote, concerns whether licensed compounding pharmacies may prepare a peptide under prescription — not whether the FDA has approved it as a drug. As of June 2026 the process is still moving; verify the current status before relying on it.

Why don't you name the worst shops or labs?

This report is aggregate by design. Per-shop and per-lab judgements belong on the individual shops and lab-tests pages, where each is assessed on its own verifiable record rather than singled out inside a market-wide summary.

This report is for educational and informational purposes only and does not constitute medical advice. Purity and identity testing describe a product's composition, not its safety or effectiveness. The peptides discussed are largely investigational compounds not approved by the FDA, the EMA, or other regulators (including Sweden's Läkemedelsverket) for human use, and many are sold for research use only; laws vary by country and change frequently. Regulatory status described here was verified as of June 2026 and should be re-checked before relying on it. The figures reflect independent lab tests submitted to Peptigrity, not a randomised survey of the entire market. Peptigrity is an independent review platform that does not sell, endorse, or recommend specific products or vendors, and earns no advertising, sponsorship, or affiliate revenue. Always consult a qualified healthcare provider before making any decision about a peptide or research compound.